Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Candel Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Candel Therapeutics, Inc.

CADL

Candel Therapeutics, Inc.

About Candel Therapeutics, Inc.

Candel Therapeutics develops off-the-shelf viral immunotherapies targeting solid tumors. Its platforms utilize genetically engineered adenoviruses and herpes simplex viruses to induce tumor cell death and stimulate systemic anti-tumor immune responses. Key products, including CAN-2409 and CAN-3110, aim to treat cancers like prostate, lung, pancreatic, and glioma by converting "cold" tumors into "hot," enhancing immune recognition, with a focus on combination therapies and regulatory approval pathways.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Candel Therapeutics, Inc.

1
1
Candel Therapeutics, Inc. Candel Therapeutics Reports $8.9 Million Net Loss Amid Increased Operating Expenses

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Candel Therapeutics, Inc. Candel Therapeutics Reports Financial Results and Operational Progress in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Candel Therapeutics, Inc. Candel Therapeutics Reports $8.7 Million Net Loss for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Candel Therapeutics, Inc. Candel Therapeutics Reports Improved Financial Results for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Candel Therapeutics, Inc. Candel Therapeutics Reports $7.4 Million Net Income in Q1 2025, Significant Turnaround from Prior Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Candel Therapeutics, Inc. Candel Therapeutics Reports $55.2 Million Net Loss for 2024, Highlights Positive Clinical Trial Data

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Candel Therapeutics, Inc. Candel Therapeutics Reports Significant Financial Challenges, Faces Doubt Over Ability to Continue as a Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments